Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Shantha Biotechnics Consents to Manufacture Dengue Vaccine

  • Shantha Biotechnics will manufacture InViragen’s dengue vaccine candidate under an agreement between the two companies. This vaccine will be used to complete preclinical studies and initiate testing of its safety and efficacy in humans.

    The vaccine was designed by collaborators at the CDC to protect against all four of the dengue viruses. "InViragen and the CDC are using innovative recombinant technologies to create a novel vaccine," says Varaprasad Reddy, M.D., managing director of Shantha Biotechnics.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »